Clinical and transcriptional response to the long-acting interleukin-1 blocker canakinumab in Blau syndrome-related uveitis

Morphologic and immunohistochemical characterization of granulomas in the nucleotide oligomerization domain 2–related disorders Blau syndrome and Crohn disease

(2012) Carl E.I. Janssen et al.   JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY

Blau syndrome revisited

(2011) Carlos D. Rose et al.   CURRENT OPINION IN RHEUMATOLOGY

Uveitis in Blau syndrome from a de novo mutation of the NOD2/CARD15 gene

(2011) Veena Rao Raiji et al.   JOURNAL OF AAPOS

Identification of Blau Syndrome disease signatures

(2011) KP Foley et al.   Pediatric Rheumatology

A multicentre, randomised, double-blind, placebo-controlled trial with the interleukin-1 receptor antagonist anakinra in patients with systemic-onset juvenile idiopathic arthritis (ANAJIS trial)

(2010) P. Quartier et al.   ANNALS OF THE RHEUMATIC DISEASES

Interleukin-1β suppression in Blau syndrome: Comment on the article by Martin et al

(2009) Junya Masumoto et al.   ARTHRITIS AND RHEUMATISM

TheNOD2defect in Blau syndrome does not result in excess interleukin-1 activity

(2009) Tammy M. Martin et al.   ARTHRITIS AND RHEUMATISM

Use of Canakinumab in the Cryopyrin-Associated Periodic Syndrome

(2009) Helen J. Lachmann et al.   NEW ENGLAND JOURNAL OF MEDICINE

A Modular Analysis Framework for Blood Genomics Studies: Application to Systemic Lupus Erythematosus

(2008) Damien Chaussabel et al.   IMMUNITY

Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled, withdrawal phase III trial

(2008) Shumpei Yokota et al.   LANCET